** Shares of Neuren Pharmaceuticals NEU.AX rise as much as 8.1% to A$14.350, their highest since Oct. 7

** Biopharmaceutical reports Rett syndrome drug Daybue's 9 months net sales exceeded full-year threshold of $250 mln

** Co sees full-year income to be in the range of A$216 mln to A$218 mln ($141.83 mln to $143.14 mln)

** Stock down 43.1% YTD as of 0046 GMT

($1 = 1.5230 Australian dollars)

(Reporting by Kumar Tanishk in Bengaluru)

((Tanishk.Kumar@thomsonreuters.com))